ASPG and acute lymphoblastic leukemia: Many experts have documented the benefit of routinely measuring asparaginase activity in all cases receiving the ALL protocol as the standard of care, because silent inactivation may cause the drug to fall below the cut-off values without clinical notice (van der Sluis et al., 2016).